Open AccessProgression of knowledge in diabetes mellitus and covid-19
Author(s) -
VL Asha Latha
Publication year - 2021
Publication title -
international journal of clinical biochemistry and research
Language(s) - English
Resource type - Journals
eISSN - 2394-6377
pISSN - 2394-6369
DOI - 10.18231/j.ijcbr.2021.035
Subject(s) - diabetes mellitus , disease , pandemic , glycemic , medicine , immunology , covid-19 , immunity , intensive care medicine , coronavirus , immune system , infectious disease (medical specialty) , endocrinology
The Coronavirus Disease 19 (COVID-19) is a pandemic infectious disease caused by the novel corona virus Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2). Diabetes mellitus (DM) and hyperglycemia are among the major comorbidities in patients with COVID-19 which might modulate immune and inflammatory responses leading to poor outcomes. Several reports show that patients with DM and COVID-19 are at an increased risk for developing severe complications including acute respiratory distress syndrome, multi-organ failure, and death. Furthermore, compromised innate immunity, pro-inflammatory cytokine milieu, reduced expression of ACE-2 and use of renin-angiotensin-aldosterone system antagonists in diabetic patients may also contribute to poor prognosis in COVID-19. However, the mechanisms underlying the relationship between COVID-19 and DM remain to be elucidated. The severity and mortality was significantly higher in diabetic patients which may predispose patients with COVID-19 to poor outcomes. Most of these conclusions are preliminary, and further investigation of the optimal management in diabetic patients is necessary. Thus, it is imperative that diabetic patients should take all necessary precautions and ensure good glycemic control amid with COVID-19 pandemic.